Values First Advisors, Inc. Freeline Therapeutics Holdings PLC Transaction History

Values First Advisors, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 20, 2022	BUY	$0.69 - $1.12 $4,244 - $6,889	6,151 Added 12.27%	56,300 $49,000
Q1 2022 May 03, 2022	BUY	$0.92 - $2.03 $24,932 - $55,015	27,101 Added 117.59%	50,149 $56,000
Q4 2021 Mar 10, 2022	BUY	$1.97 - $3.45 $45,404 - $79,515	23,048 New	23,048 $46,000
Q3 2021 Nov 15, 2022	SELL	$3.04 - $8.9 $107,533 - $314,819	-35,373 Reduced 62.83%	20,927 $71,000

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.